Literature DB >> 33581844

Diabetic macular edema.

Melissa Ixcamey1, Camille Palma2.   

Abstract

Diabetic retinopathy (DR) is a leading cause of preventable blindness world-wide. Diabetic macular edema (DME) is the most common cause of moderate vision loss in patients with diabetes. Although treatments for DME have improved significantly over the past decades, the burden of this disease remains high for patients and the healthcare system alike. The role of the primary care provider is critical in the prevention and prompt referral for management of DME.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Anti-VEGF; Diabetic macular edema; Diabetic retinopathy; Fluorescein angiography; Optical coherence tomography

Mesh:

Substances:

Year:  2021        PMID: 33581844     DOI: 10.1016/j.disamonth.2021.101138

Source DB:  PubMed          Journal:  Dis Mon        ISSN: 0011-5029            Impact factor:   3.800


  3 in total

Review 1.  Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.

Authors:  Muhammad Z Chauhan; Peyton A Rather; Sajida M Samarah; Abdelrahman M Elhusseiny; Ahmed B Sallam
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

2.  The Functional Vision Restorative Effect of Crocin via the BDNF-TrkB Pathway: An In Vivo Study.

Authors:  Jia-Lain Wu; Shih-Liang Yang; Yung-Chuan Ho; Chao-Hsiang Chen; Bing-Rong Tasi; Meng-Chih Lee; Bo-Yie Chen
Journal:  Nutrients       Date:  2022-04-20       Impact factor: 6.706

Review 3.  The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy.

Authors:  Matteo Tassetto; Anna Scialdone; Anna Solini; Francesco Di Virgilio
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.